News - Cymbalta


Current filters:


Popular Filters

Eli Lilly exceeds expectations with third quarter results

Eli Lilly exceeds expectations with third quarter results


US pharma major Eli Lilly has announced financial results for the third quarter of 2013. Despite the…

AlimtaAmyvidAxironCialisCymbaltaEffientEli LillyEvistaFinancialForteoHumalogNorth AmericaPharmaceuticalStratteraTrajentaZyprexa

Eli Lilly records higher than expected earnings in 2nd-qtr results


US drug major Eli Lilly's (NYSE: LLY) recorded higher than expected earnings as growth in key products…

AlimtaCialisCymbaltaEffientEli LillyEvistaFinancialForteoHumalogNorth AmericaPharmaceuticalStratteraZyprexa

Lilly/Boehringer Ingelheim's Cymbalta now fibromyalgia market leader in USA


US drug major Eli Lilly (NYSE: LLY) and German independent Boehringer Ingelheim's Cymbalta (duloxetine)…

Boehringer IngelheimCymbaltaEli LillyGlobalLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

Eli Lilly gains six months US pediatric exclusivity for Cymbalta


US drug major Eli Lilly (NYSE: LLY) announced that it has met the US Food and Drug Administration requirements…

CymbaltaEli LillyNeurologicalNorth AmericaPharmaceuticalRegulation

Global pain management drugs market to see moderate growth as generic share continues to rise


In 2010, the global pain management market was worth approximately $28.6 billion, representing a compound…

CelebrexCymbaltaEli LillyGlobalLyricaMarkets & MarketingNeurologicalPfizerPharmaceutical

Pfizer’s Pristiq sees private plan formulary access similar to Lilly’s Cymbalta


In the USA, similar percentages of private health plan lives have formulary access to Pfizer’s (NYSE:…

CymbaltaEli LillyHealthcareNeurologicalNorth AmericaPfizerPharmaceuticalPricingPristiq

Back to top